| abstract |
The present invention relates to a new class of compounds that are inhibitors of interleukin-1β converting enzymes. The ICE inhibitors of the present invention are characterized by their specific structural and physicochemical properties. The invention also relates to pharmaceutical compositions comprising such compounds. The compounds and pharmaceutical compositions of the invention are particularly suitable for inhibiting ICE activity, and include IL-1-mediated diseases, apoptosis-mediated diseases, IGIF-mediated diseases and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, It may be advantageous to use as an agent for destructive bone disease, proliferative disease, infectious disease, degenerative disease and necrotic disease. In addition, the present invention inhibits ICE activity, treats interleukin-1-mediated disease, apoptosis-mediated disease, IGIF-mediated disease and IFN- [gamma] -mediated disease, and uses IGIF and A method for reducing the production of IFN- [gamma]. The present invention also relates to a process for preparing an N-acylamino compound. |